Halozyme治疗报告称,收入增长4.67%,净利润40.3%,分析员的价格目标从52美元到65美元不等。 Halozyme Therapeutics reports 4.67% revenue growth and 40.3% net margin, with analysts' price targets ranging from $52 to $65.

专注于瘤治疗的Halozyme Therapeutics (纳斯达克:HALO) 的市场上市值低于行业标准,截至2024年6月30日,其收入增长了4.67%. Halozyme Therapeutics (NASDAQ: HALO), focused on oncology therapies, has a market cap below industry standards and reported a 4.67% revenue growth as of June 30, 2024. 尽管如此,它仍然有40.3%的强劲净差。 Despite this, it boasts a strong net margin of 40.3%. 分析员的看法各异,导致平均12个月价格指标为62.50美元,高于60.92美元。 Analysts' views vary, leading to an average 12-month price target of $62.50, up from $60.92. 主要分析师维持或调整其评级,有几位分析师建议采用52美元至65美元的价格“Buy”。 Key analysts maintain or adjust their ratings, with several recommending a "Buy" at prices ranging from $52 to $65.